SPRO

Spero Therapeutics, Inc. (SPRO) | Rumor.io

Spero Therapeutics

SPRO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,395

Bullish sentiment (50-day avg)57%

Price to earnings ratio8.5

Market capitalization69.3M

Earnings per share0.14

Dividend yield (TTM)—

Revenue (annual)59.6M

Net income (annual)8.6M

Social

What share of all stock conversation is about SPRO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 22

Spero Therapeutics' Utebzi has the potential to reach "blockbuster" status, exceeding $1 billion in annual sales by 2030, according to optimistic financial analysts.
The company's peak sales target for Utebzi, as part of a trio of antimicrobial launches, is estimated to exceed £2 billion (~$2.6 billion USD) annually.
Spero Therapeutics' market value is expected to increase significantly, with some analysts predicting annual revenue of $200-300 million, making it an attractive long-term investment opportunity.

Generated by AI

Sentiment

Of the messages about SPRO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	75% +25	83.02% -3.12
Bearish	—	—	25% -25	16.98% +3.12

Bullish· Jun 18

$SPRO is poised to announce positive news, potentially leading to a significant price increase.
Strong buying interest and low cash burn requirements could contribute to a substantial price surge, potentially exceeding $4.
Institutional and insider ownership is substantial, with around 50% ownership, which could provide support for the stock and lead to further buying interest.

Bearish· Jun 18

$SPRO's price action may be influenced by the FDA's approval process and potential reverse merger into an oncology play.
Large investment funds may have closed their positions in $SPRO due to internal regulations prohibiting holdings in micro-cap companies during binary events.
$SPRO's recent price pop may have lacked follow-through, suggesting a lack of real demand and potentially indicating that the move was driven by noise rather than fundamental support.

Generated by AI

Topics

Of the messages about SPRO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	94.44%
Earnings	0%	0%	0%	1.28%
Macro	0%	0%	0%	0.71%
Controversies	0%	0%	0%	1.71%
Analysts	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	1.85%

Earnings· Aug 9

Spero Therapeutics reported earnings that beat expectations by $0.09.
However, the company missed revenue estimates.
This indicates a potential mixed performance in the earnings report.

Announcements· Jul 14

Spero Therapeutics has licensed SP001, a Phase 2-ready anti-CD40L antibody, from Innovent Biologics in a deal worth up to $1.1 billion in milestones plus royalties.
The deal provides Spero with exclusive global rights (excluding Greater China) to develop, manufacture, and commercialize SP001, with a Phase 2 trial targeting IgG4-related disease first.
Spero has secured $105 million in non-dilutive financing from KKR affiliate, backed by future Utebzi payments from GSK, extending its cash runway to 2H 2029 while funding SP001 development.

Controversies· Jun 2

A class action lawsuit has been filed against Spero Therapeutics, Inc. (SPRO) by Bragar Eagel & Squire, P.C., and The Portnoy Law Firm, alleging investor losses.
The Law Offices of Frank R. Cruz is investigating Spero Therapeutics, Inc. (SPRO) on behalf of investors, possibly indicating a potential lawsuit.
Spero Therapeutics, Inc. (SPRO) has been the subject of a collective 82% drop, according to a video comment, highlighting investor concerns and potential losses.

Technical Analysis· May 28

The 5-minute chart shows a "perfect cup and handle" formation, which could indicate a potential breakout.
Strong support is present at $2.00, and a "little wall" at $2.10 could be a resistance level.
The stock is testing the 50 MA, and a break above $2.4 is possible, but the author is uncertain if it will happen.

Generated by AI

Community

Of the messages about SPRO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	30%	53.57%	45.73%
Newcomers	100%	70%	46.43%	54.27%

Regulars· May 30

Spero Therapeutics' stock is expected to maintain support in the 2.40s, with a potential range to $3.20+.
The stock's recent price action is viewed as a strong indication of continuation, with a 57x relative volume gap up two days ago and a low volume inside bar day.
The early efficacy of Spero Therapeutics' trial with GSK is seen as a significant positive, with the stock's price movement following the news.

Newcomers· Jun 17

Newcomers are optimistic about a potential buyout, with some setting a target price of $9 and anticipating a 300% gain.
The FDA approval of Spero Therapeutics' Utebzi has been met with concerns about the company's stock price, with some attributing the sell-off to the delayed availability of the treatment until the end of 2026.
There is uncertainty about the potential acquisition of Spero Therapeutics by GlaxoSmithKline, with some speculating that GSK may buy the company while others are waiting to see how sales go.

Generated by AI

News

H.C. Wainwright raises Spero Therapeutics price target to $6

16d agoInvesting.com

Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary

Moby summary of Spero Therapeutics, Inc.'s Q2 2026 earnings call

1mo agoYahoo Finance

Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...

SPRO strengthens its balance sheet and extends cash runway into 2029 while advancing its new SP001 immunology pipeline following the landmark approval of the first oral carbapenem antibiotic.

1mo agoYahoo Finance

Spero Therapeutics Q2 Earnings Call Highlights

Spero Therapeutics (NASDAQ:SPRO) used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-related disease. Presi

1mo agoYahoo Finance

Earnings call transcript: Spero Therapeutics posts small q2 2026 EPS beat

1mo agoInvesting.com

Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript

Detailed price information for Pfizer Inc (PFE-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about SPRO also mention

#	Name	Attention
1	Shuttle Pharmaceuticals Holdings, Inc.SHPH	0%0
2	Comera Life Sciences Holdings Inc.CMRA	0%0
3	VIGL - Vigil Neuroscience, Inc.	——
4	MGAM - Mobile Global Esports Inc.	——
5	LVTX - LAVA Therapeutics N.V.	——
6	Iterum Therapeutics plcITRM	0%0
7	Galapagos NV American Depositary ReceiptGLPG	0%0
8	GSK plc ADRGSK	0%0
9	Assembly Biosciences Inc.ASMB	0%new
10	Vera Therapeutics Inc.VERA	0%new

Spero Therapeutics, Inc.

Healthcare
Biotechnology

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Spero Therapeutics advances a pipeline of product candidates aimed at serious infectious and immune-mediated conditions, including tebipenem pivoxil, an oral carbapenem antibiotic for complicated urinary tract infections, SPR720 for nontuberculous mycobacterial pulmonary disease, SPR206 for difficult Gram-negative infections, and SP001 for immune-mediated disease. The company’s work centers on addressing high unmet medical needs in hospital, outpatient, and specialty care settings through novel small-molecule and biologic therapies. Headquartered in Cambridge, Massachusetts, Spero Therapeutics plays a role in the biopharmaceutical market by focusing on differentiated medicines for patients with limited treatment options.

Website

Location

675 Massachusetts Avenue

Cambridge, MA, 02139

United States

Social

What share of all stock conversation is about SPRO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Sep 22

Spero Therapeutics' Utebzi has the potential to reach "blockbuster" status, exceeding $1 billion in annual sales by 2030, according to optimistic financial analysts.
The company's peak sales target for Utebzi, as part of a trio of antimicrobial launches, is estimated to exceed £2 billion (~$2.6 billion USD) annually.
Spero Therapeutics' market value is expected to increase significantly, with some analysts predicting annual revenue of $200-300 million, making it an attractive long-term investment opportunity.

Generated by AI

Sentiment

Of the messages about SPRO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	75% +25	83.02% -3.12
Bearish	—	—	25% -25	16.98% +3.12

Bullish· Jun 18

$SPRO is poised to announce positive news, potentially leading to a significant price increase.
Strong buying interest and low cash burn requirements could contribute to a substantial price surge, potentially exceeding $4.
Institutional and insider ownership is substantial, with around 50% ownership, which could provide support for the stock and lead to further buying interest.

Bearish· Jun 18

$SPRO's price action may be influenced by the FDA's approval process and potential reverse merger into an oncology play.
Large investment funds may have closed their positions in $SPRO due to internal regulations prohibiting holdings in micro-cap companies during binary events.
$SPRO's recent price pop may have lacked follow-through, suggesting a lack of real demand and potentially indicating that the move was driven by noise rather than fundamental support.

Generated by AI

Topics

Of the messages about SPRO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	94.44%
Earnings	0%	0%	0%	1.28%
Macro	0%	0%	0%	0.71%
Controversies	0%	0%	0%	1.71%
Analysts	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	1.85%

Earnings· Aug 9

Spero Therapeutics reported earnings that beat expectations by $0.09.
However, the company missed revenue estimates.
This indicates a potential mixed performance in the earnings report.

Announcements· Jul 14

Spero Therapeutics has licensed SP001, a Phase 2-ready anti-CD40L antibody, from Innovent Biologics in a deal worth up to $1.1 billion in milestones plus royalties.
The deal provides Spero with exclusive global rights (excluding Greater China) to develop, manufacture, and commercialize SP001, with a Phase 2 trial targeting IgG4-related disease first.
Spero has secured $105 million in non-dilutive financing from KKR affiliate, backed by future Utebzi payments from GSK, extending its cash runway to 2H 2029 while funding SP001 development.

Controversies· Jun 2

A class action lawsuit has been filed against Spero Therapeutics, Inc. (SPRO) by Bragar Eagel & Squire, P.C., and The Portnoy Law Firm, alleging investor losses.
The Law Offices of Frank R. Cruz is investigating Spero Therapeutics, Inc. (SPRO) on behalf of investors, possibly indicating a potential lawsuit.
Spero Therapeutics, Inc. (SPRO) has been the subject of a collective 82% drop, according to a video comment, highlighting investor concerns and potential losses.

Technical Analysis· May 28

The 5-minute chart shows a "perfect cup and handle" formation, which could indicate a potential breakout.
Strong support is present at $2.00, and a "little wall" at $2.10 could be a resistance level.
The stock is testing the 50 MA, and a break above $2.4 is possible, but the author is uncertain if it will happen.

Generated by AI

Community

Of the messages about SPRO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	30%	53.57%	45.73%
Newcomers	100%	70%	46.43%	54.27%

Regulars· May 30

Spero Therapeutics' stock is expected to maintain support in the 2.40s, with a potential range to $3.20+.
The stock's recent price action is viewed as a strong indication of continuation, with a 57x relative volume gap up two days ago and a low volume inside bar day.
The early efficacy of Spero Therapeutics' trial with GSK is seen as a significant positive, with the stock's price movement following the news.

Newcomers· Jun 17

Newcomers are optimistic about a potential buyout, with some setting a target price of $9 and anticipating a 300% gain.
The FDA approval of Spero Therapeutics' Utebzi has been met with concerns about the company's stock price, with some attributing the sell-off to the delayed availability of the treatment until the end of 2026.
There is uncertainty about the potential acquisition of Spero Therapeutics by GlaxoSmithKline, with some speculating that GSK may buy the company while others are waiting to see how sales go.

Generated by AI

Spero Therapeutics

Social

Sep 22

Bullish· Jun 18

Bearish· Jun 18

Earnings· Aug 9

Announcements· Jul 14

Controversies· Jun 2

Technical Analysis· May 28

Regulars· May 30

Newcomers· Jun 17

H.C. Wainwright raises Spero Therapeutics price target to $6

Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary

Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...

Spero Therapeutics Q2 Earnings Call Highlights

Earnings call transcript: Spero Therapeutics posts small q2 2026 EPS beat

Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript

Also Discussed

Spero Therapeutics, Inc.

Company Information

Location

H.C. Wainwright raises Spero Therapeutics price target to $6

Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary

Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...

Spero Therapeutics Q2 Earnings Call Highlights

Earnings call transcript: Spero Therapeutics posts small q2 2026 EPS beat

Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript

Also Discussed

Social

Sep 22

Bullish· Jun 18

Bearish· Jun 18

Earnings· Aug 9

Announcements· Jul 14

Controversies· Jun 2

Technical Analysis· May 28

Regulars· May 30

Newcomers· Jun 17